How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about palopegteriparatide

Marketing authorisation indication

2.1

Palopegteriparatide (Yorvipath, Ascendis Pharma) is 'a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism'.

Price

2.3

The list price is £7,406.00 per pack of 2 pre-filled multiuse disposable injection pens (excluding VAT; BNF online accessed October 2025). Pens are available in different doses.

2.4

The company has a commercial arrangement, which would have applied if palopegteriparatide had been recommended.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Ascendis Pharma will be included here when guidance is published.